AR089957A1 - Combinaciones farmaceuticas, combinaciones sinergicas - Google Patents
Combinaciones farmaceuticas, combinaciones sinergicasInfo
- Publication number
- AR089957A1 AR089957A1 ARP130100415A ARP130100415A AR089957A1 AR 089957 A1 AR089957 A1 AR 089957A1 AR P130100415 A ARP130100415 A AR P130100415A AR P130100415 A ARP130100415 A AR P130100415A AR 089957 A1 AR089957 A1 AR 089957A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- solvated
- combinations
- effective amount
- Prior art date
Links
- 230000002195 synergetic effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 8
- 239000012453 solvate Substances 0.000 abstract 4
- 239000002904 solvent Substances 0.000 abstract 4
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 3
- 208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 3
- 239000000048 adrenergic agonist Substances 0.000 abstract 3
- 229940126157 adrenergic receptor agonist Drugs 0.000 abstract 3
- 208000020629 overactive bladder Diseases 0.000 abstract 3
- 229960001551 mirabegron Drugs 0.000 abstract 2
- PBAPPPCECJKMCM-IBGZPJMESA-N mirabegron Chemical compound S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 PBAPPPCECJKMCM-IBGZPJMESA-N 0.000 abstract 2
- LLDXOPKUNJTIRF-QFIPXVFZSA-N solabegron Chemical compound C([C@H](O)C=1C=C(Cl)C=CC=1)NCCNC(C=1)=CC=CC=1C1=CC=CC(C(O)=O)=C1 LLDXOPKUNJTIRF-QFIPXVFZSA-N 0.000 abstract 2
- 229950009659 solabegron Drugs 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- FUZBPOHHSBDTJQ-CFOQQKEYSA-L disodium;5-[(2r)-2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate Chemical compound [Na+].[Na+].C1([C@@H](O)CN[C@@H](CC=2C=C3OC(OC3=CC=2)(C([O-])=O)C([O-])=O)C)=CC=CC(Cl)=C1 FUZBPOHHSBDTJQ-CFOQQKEYSA-L 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 206010029446 nocturia Diseases 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
- 229960004045 tolterodine Drugs 0.000 abstract 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 abstract 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261596893P | 2012-02-09 | 2012-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089957A1 true AR089957A1 (es) | 2014-10-01 |
Family
ID=48948043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100415A AR089957A1 (es) | 2012-02-09 | 2013-02-08 | Combinaciones farmaceuticas, combinaciones sinergicas |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2811989A1 (fr) |
| JP (1) | JP2015509931A (fr) |
| KR (1) | KR20150020160A (fr) |
| CN (1) | CN104684549A (fr) |
| AR (1) | AR089957A1 (fr) |
| AU (1) | AU2013216864A1 (fr) |
| CA (1) | CA2864173A1 (fr) |
| HK (1) | HK1204966A1 (fr) |
| IL (1) | IL234033A0 (fr) |
| PH (1) | PH12014501814A1 (fr) |
| SG (1) | SG11201404776PA (fr) |
| TW (1) | TW201338772A (fr) |
| WO (1) | WO2013119910A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| EP3226849A4 (fr) | 2014-12-03 | 2018-05-09 | Velicept Therapeutics, Inc. | Compositions et procédés d'utilisation du solabégron à libération modifiée pour traiter des symptômes du bas appareil urinaire |
| US10065922B2 (en) | 2015-10-23 | 2018-09-04 | Velicept Therapeutics, Inc. | Solabegron zwitterion and uses thereof |
| KR101868438B1 (ko) | 2017-04-13 | 2018-06-20 | (주) 성운파마코피아 | 아미드 유도체의 제조방법 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL124473C (fr) | 1960-07-26 | |||
| US5677346A (en) | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
| US6123961A (en) | 1996-09-25 | 2000-09-26 | Bridge Pharma, Inc. | Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin |
| GB9812709D0 (en) | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
| GB9929297D0 (en) | 1999-12-11 | 2000-02-02 | Glaxo Group Ltd | Process |
| GB0102407D0 (en) | 2001-01-31 | 2001-03-14 | Glaxo Group Ltd | Process |
| TWI295669B (en) * | 2002-10-30 | 2008-04-11 | Theravance Inc | Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds |
| EP1424079A1 (fr) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine |
| AU2008233232A1 (en) * | 2007-03-29 | 2008-10-09 | Merck Sharp & Dohme Corp. | Combination therapy for the treatment-of lower urinary tract symptoms |
| PE20091825A1 (es) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
| EP2470021B1 (fr) | 2009-08-27 | 2014-10-22 | Merck Sharp & Dohme Corp. | Nouveaux agonistes de récepteurs adrénergiques bêta 3 dérivés de pyrrolidine |
| JP5738871B2 (ja) * | 2009-10-07 | 2015-06-24 | メルク・シャープ・エンド・ドーム・コーポレイション | β３アドレナリン作動性受容体アゴニスト及び抗ムスカリン剤を用いる併用療法 |
-
2013
- 2013-02-08 AR ARP130100415A patent/AR089957A1/es unknown
- 2013-02-08 SG SG11201404776PA patent/SG11201404776PA/en unknown
- 2013-02-08 EP EP13704702.3A patent/EP2811989A1/fr not_active Withdrawn
- 2013-02-08 WO PCT/US2013/025285 patent/WO2013119910A1/fr not_active Ceased
- 2013-02-08 TW TW102105243A patent/TW201338772A/zh unknown
- 2013-02-08 AU AU2013216864A patent/AU2013216864A1/en not_active Abandoned
- 2013-02-08 CN CN201380019041.9A patent/CN104684549A/zh active Pending
- 2013-02-08 CA CA2864173A patent/CA2864173A1/fr not_active Abandoned
- 2013-02-08 KR KR20147023969A patent/KR20150020160A/ko not_active Withdrawn
- 2013-02-08 JP JP2014556709A patent/JP2015509931A/ja active Pending
- 2013-02-08 HK HK15105751.1A patent/HK1204966A1/xx unknown
-
2014
- 2014-08-10 IL IL234033A patent/IL234033A0/en unknown
- 2014-08-11 PH PH12014501814A patent/PH12014501814A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150020160A (ko) | 2015-02-25 |
| HK1204966A1 (en) | 2015-12-11 |
| JP2015509931A (ja) | 2015-04-02 |
| TW201338772A (zh) | 2013-10-01 |
| EP2811989A1 (fr) | 2014-12-17 |
| IL234033A0 (en) | 2014-09-30 |
| SG11201404776PA (en) | 2014-09-26 |
| AU2013216864A1 (en) | 2014-09-11 |
| WO2013119910A1 (fr) | 2013-08-15 |
| CN104684549A (zh) | 2015-06-03 |
| CA2864173A1 (fr) | 2013-08-15 |
| PH12014501814A1 (en) | 2014-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6680685A2 (es) | Combinaciones de agonistas del receptor beta 3-adrenergetico y antagonistas del receptor muscarínico para tratar vejiga hiperactiva | |
| AR089957A1 (es) | Combinaciones farmaceuticas, combinaciones sinergicas | |
| CL2023003794A1 (es) | Agonista del receptor de glp-1 y composición y uso del mismo | |
| ECSP11010948A (es) | Inhibidores de las enzimas de proteína cinasa activadas por | |
| UY36660A (es) | Combinaciones de inhibidores de irak4 | |
| BR112017017135A2 (pt) | inibidores de tgf-beta | |
| DOP2012000132A (es) | Composicion farmaceutica que comprende un agonista de glp-1 y metionina | |
| CR20120218A (es) | Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina | |
| CO6180437A2 (es) | Derivados de sulfonamida como agonistas adrenergicos y antagonistas muscarinicos | |
| PE20151555A1 (es) | Agentes inductores de la apoptosis para tratar el cancer y enfermedades inmunes y autoinmunes | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| AR093038A1 (es) | Conjugados de suministro de farmacos que contienen aminoacidos no naturales y metodos para usarlos, composicion y uso | |
| GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| AR094910A1 (es) | COMBINACIONES QUE COMPRENDEN COMPUESTOS ANTAGONISTAS MUSCARÍNICOS - AGONISTAS b2 (MABA) | |
| CL2013002241A1 (es) | Compuestos derivados de (4,4´-bifeniilbis(1h-imidazol-4,2-diil)-2,1-pirrolidindiil((1s)-1-((2r,6r)-2,4-dimetilltetrahidro-2h-piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo, inhibidores del vhc; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso para tratar una infeccion por vhc. | |
| ECSP14013340A (es) | Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenérgicos ?2 y como antagonistas muscarínicos m3 | |
| AR089269A1 (es) | Composiciones para el cuidado oral | |
| AR085616A1 (es) | Composicion farmaceutica inhalable que comprende glicopirrolato, uso | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| MX2018007296A (es) | Compuestos de isoindol. | |
| MX382156B (es) | Sondas para formar imagenes de proteina de huntingtina. | |
| AR095015A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| CL2018001408A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| CL2013000599A1 (es) | Compuestos derivados de diciano-piridina, agonistas selectivos de adenosina a1, para su uso en un procedimiento para el tratamiento y/o profilaxis de glaucoma, glaucoma normotensivo, hipertension ocular y/o combinaciones de los mismos; y composicion farmaceutica que comprende a uno de dichos compuestos. | |
| ES2611776T3 (es) | Uso de sales de tungsteno (VI) para el tratamiento de la esterilidad femenina en mamíferos no diabéticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |